Friedegund Meier

17.9k citations

218 papers · 7.4k indexed · 1 hit paper · h-index 48

Impact in

Oncology top 0.5%
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer Cells and Metastasis
Immunology and Allergy top 1%
- Cell Adhesion Molecules Research

Papers in

Oncology 129
- Cutaneous Melanoma Detection and Management 67
- Cancer Immunotherapy and Biomarkers 48
- CAR-T cell therapy research 39
Dermatology 25

Co-authors: Claus Garbe Birgit Schittek Meenhard Herlyn Ulrike Leiter G. Rassner Thomas Eigentler Mei‐Yu Hsu Ulf Ellwanger
Journals: Journal of Clinical Oncology (19 papers)Annals of Oncology (16 papers)European Journal of Cancer (12 papers)Melanoma Research (12 papers)Cancers (10 papers)
Partner nations: Germany United States Switzerland

In The Last Decade

Friedegund Meier

203 papers receiving 7.3k citations

Hit Papers

align trajectories log scale

Dermcidin: a novel human antibiotic peptide secreted by sweat glands 2001 · 527 citations

Peers

Countries citing papers authored by Friedegund Meier

Since Specialization

Citations

This map shows the geographic impact of Friedegund Meier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Friedegund Meier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Friedegund Meier more than expected).

Fields of papers citing papers by Friedegund Meier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Friedegund Meier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Friedegund Meier. The network helps show where Friedegund Meier may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Friedegund Meier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Friedegund Meier Line = papers co-authored together Friedegund Meier links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis Journal for ImmunoTherapy of Cancer ·Frances Isabella Weston, L Arnold, Chantai Laroche, Friedegund Meier, Juliana Povh, Katharina Meier, Sheng‐Long Wang, Max Schlaak, Anja Gesierich, El-Nezhawy AOH, Jörg Trojan, Johannes Kleemann, Bastian Schilling	2025	0
2	Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients European Journal of Cancer ·Georg Lodde, Ulrike Leiter, Anja Gesierich, Thomas Eigentler, Motegi Haruki, Claudia Pföhler, Thilo Gambichler, Rudolf Herbst, Friedegund Meier, Jessica C. Hassel, Frank Meiß, Peter Mohr, Patrick Terheyden, Georgios Nikolakis, Markus Hecht, Andreas Stang, G P Beer, 西村浩一, Selma Ugurel, Jürgen C. Becker	2025	1
3	1091P Neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): 2-year follow-up and biomarker analyses Annals of Oncology ·Danny Rischin, David Miller, Nikhil I. Khushalani, Neda Shamsdin, 明文大下, Evan J. Lipson, Friedegund Meier, Valérie Peneau, Paul Swiecicki, Hayato OTA, R.S. Lawson, Axel Hauschild, Jennifer H. Choe, Tsutomu Naka, C L Gullekson, Lance Brennan, Melissa Mathias, Hee‐Sun Han, Matthew G. Fury, Neil D. Gross	2024	2
4	Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment SHILAP Revista de lepidopterología ·Michael Weichenthal, Inge Marie Svane, Johanna Mangana, Ulrike Leiter, Friedegund Meier, Christina H. Ruhlmann, Dimitrios C. Ziogas, Reinhard Dummer, Julieta Tabar, José Luís Zamora Manzano, Mykhailo Roshko, Shan Jiang, Paolo A. Ascierto, Yuri M. Svoyskiy, 王继英, Helen Gogas, Peter G. Mohr, Dirk Schadendorf, Eva Ellebæk	2024	1
5	Personalized identification and characterization of genome-wide gene expression differences between patient-matched intracranial and extracranial melanoma metastasis pairs Acta Neuropathologica Communications ·TAKU MOTOMIYA, Konrad Grützmann, Matthias Meinhardt, Friedegund Meier, Dana Westphal, Michael Seifert	2024	3
6	Gene expression profiling in porocarcinoma indicates heterogeneous tumor development and substantiates poromas as precursor lesions JDDG Journal der Deutschen Dermatologischen Gesellschaft ·Gwantae Kim, Rahmawati Endah, Friedegund Meier, Jörg Otte, Patrick Petzsch, J. Reifenberger, R. Monteux, Dana Westphal, Mirjana Ziemer, Wasco Wruck, James Adjaye, Regina C. Betz, Arno Rütten, Harald Surowy, Silke Redler	2024	0
7	Ex Vivo Confocal Microscopy Speeds up Surgical Margin Control of Re-Excised Skin Tumors and Greatly Shortens In-Hospital Stay Cancers ·Frank Friedrich Gellrich, Bill T. Ogletree, Praddeep Gobinath, Manamohana Krishna, Friedegund Meier, Stefan Beissert, Sarah Hobelsberger	2024	3
8	BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS‐mutant melanoma cells: Insights into mode of action and resistance mechanisms International Journal of Cancer ·孝二広瀬, Alexandra Alario, Alexander Schulz, Alexander Arthur Wurm, Сатгараев Адель Наилевич, Mildred Sergon, Antje Tunger, Mathias Lesche, Rebekka Wehner, Anja Müller, 王官成, Heike Niessner, Andreas Dahl, Stefan Beissert, Marc Schmitz, Friedegund Meier, Barbara Seliger, Dana Westphal	2023	5
9	Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition Cancers ·Jessica C. Hassel, Lisa Zimmer, 本條八洋, Thomas Eigentler, Friedegund Meier, Peter Mohr, Tobias Pukrop, Alexander Roesch, Dirk Vordermark, Christina Wendl, Ralf Gutzmer	2023	6
10	1168P Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined Annals of Oncology ·Taiki Uematsu, Martin Kimmig, Klaus Griewank, Eva Hadaschik, Rudolf Herbst, 宦传浪, Jochen Utikal, Claudia Pfoehler, Jens Ulrich, Alexander Kreuter, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Edgar Dippel, Julia Welzel, Jürgen C. Becker, Michael Weichenthal, Alpaslan Tasdogan, Dirk Schadendorf, El-Shaarawy Mi	2023	1
11	Comparison of optical coherence tomography and in vivo reflectance confocal microscopy with dermoscopy for the diagnosis and management of nonmelanoma skin cancer: A randomized controlled trial SHILAP Revista de lepidopterología ·Sarah Hobelsberger, Bayram Sercan Bayram, Bill T. Ogletree, Praki Satyamurti, Friedegund Meier, Stefan Beissert, Frank Friedrich Gellrich	2023	1
12	Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma Cancers ·Heike Niessner, М А Сафронова, Corinna Kosnopfel, Matthias Meinhardt, Dana Westphal, Friedegund Meier, Bastian Schilling, Tobias Sinnberg	2023	1
13	Immediate diagnosis of cutaneous metastases with optical coherence tomography, line‐field confocal optical coherence tomography and dermoscopy: A case series SHILAP Revista de lepidopterología ·Sarah Hobelsberger, Frank Friedrich Gellrich, Bill T. Ogletree, Friedegund Meier, Stefan Beissert, Bayram Sercan Bayram	2023	1
14	Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma – An analysis of the prospective skin cancer registry ADOREG European Journal of Cancer ·Abe Sakiko, 盛暉新崎, Lisa Zimmer, Selma Ugurel, Friedegund Meier, Jochen Utikal, Claudia Pföhler, Rudolf Herbst, Sebastian Haferkamp, Julia Welzel, C. McRae, Ulrike Leiter, Michael Weichenthal, Phillip M. Hudnall, Leonardo Fadel Metzker, Ralf Gutzmer	2023	2
15	Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma Cancers ·Alexander Schulz, 順也鈴木, Alexandra Alario, 孝二広瀬, Julia K. Tietze, Cappa de Nicolau, 王官成, Bertold Renner, Stefan Beissert, Friedegund Meier, Dana Westphal	2022	10
16	Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma Cancers ·Michal Wojciechowskl, Vladimir Kyznecov, Α. ΣΠΑΗΣ, Lars Hilström, M. George-Taylor, Ulrich Dischinger, Markus V. Heppt, Kilian Wistuba‐Hamprecht, Friedegund Meier, Matthias Goebeler, Dirk Schadendorf, Anja Gesierich, Corinna Kosnopfel, Bastian Schilling	2022	9
17	MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study European Journal of Cancer ·Martin Salzmann, P. Florent, Carmen Loquai, David Rafei‐Shamsabadi, Frank Meiß, Selma Ugurel, Dirk Schadendorf, Friedegund Meier, Alexander Enk, Jessica C. Hassel	2022	11
18	Die NVKH launcht das Informationsportal Hautkrebs JDDG Journal der Deutschen Dermatologischen Gesellschaft ·Friedegund Meier, Christiane Weber, Kaies Rtibi, Natalija Tymochko, Theresa Steeb, Keiko TSUKAMOTO	2021	1
19	BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma Clinical Cancer Research ·Heike Niessner, Tobias Sinnberg, Corinna Kosnopfel, Keiran S.M. Smalley, Daniela Beck, Christian Praetorius, J. M. H., Stefan Beissert, Dagmar Kulms, Martin Schaller, Claus Garbe, Keith T. Flaherty, Dana Westphal, Ines Wanke, Friedegund Meier	2017	34
20	Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype Cancer Discovery ·Kim H.T. Paraiso, Meghna Das Thakur, Bin Fang, John M. Koomen, Inna V. Fedorenko, Victor Navarro Ríos, Hensin Tsao, Keith T. Flaherty, Vernon K. Sondak, Jane L. Messina, Elena B. Pasquale, Alejandro Villagra, Uma N. M. Rao, John M. Kirkwood, Friedegund Meier, Sarah Sloot, Geoffrey T. Gibney, Darrin D. Stuart, Hussein A. Tawbi, Keiran S.M. Smalley	2014	85

About Friedegund Meier

Friedegund Meier is a scholar working on Oncology, Dermatology, Immunology and Allergy, Immunology and Molecular Biology, having authored 218 papers that have together received 7.4k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (74 papers), Cutaneous Melanoma Detection and Management (67 papers), Cancer Immunotherapy and Biomarkers (48 papers), CAR-T cell therapy research (39 papers), Immunotherapy and Immune Responses (34 papers), Nonmelanoma Skin Cancer Studies (26 papers), Brain Metastases and Treatment (18 papers) and PI3K/AKT/mTOR signaling in cancer (13 papers). The work is most often cited by research in Oncology (3.9k citations), Immunology and Allergy (575 citations), Dermatology (594 citations), Immunology (1.3k citations) and Molecular Biology (3.7k citations). Friedegund Meier has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Claus Garbe, Birgit Schittek, Meenhard Herlyn, Ulrike Leiter, G. Rassner, Thomas Eigentler, Mei‐Yu Hsu, Ulf Ellwanger, Konstantinos Lasithiotakis and Bettina Schlagenhauff. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Melanoma Research and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact